Could the U.S. actually build a nuclear reactor on the moon? Here's what an expert says
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 hours ago
- CTV News
Venus and Jupiter appear close in the sky as summer's best meteor shower peaks soon
In this long-exposure photo, a meteor streaks across the sky, seen above palm trees, in Bal Harbour, Fla., early Monday, Aug. 13, 2018, during the Perseid meteor shower. (AP Photo/Wilfredo Lee) WASHINGTON — Summer's most dazzling meteor shower, the Perseids, peaks early Wednesday. At the same time, Venus and Jupiter will converge in the sky — overlapping like a very bright star. If your focus is the meteor shower, it's worth knowing that this year a bright moon will dampen viewing during the pre-dawn peak, so some experts recommend waiting a week or so to glimpse shooting stars against a darker sky. The Perseids 'are an incredible meteor shower,' said Thaddeus LaCoursiere, planetarium program co-ordinator at the Bell Museum in St. Paul, Minnesota. Under dark skies with no moon, the Perseids can produce between 60 to 100 meteors per hour, he said. Since the moon will be around 84 per cent full during the peak, skywatchers might expect between 10 to 20 meteors per hour, according to the American Meteor Society. 'This year I'm actually recommending that people go out a little bit later' — a week or so past the peak when the moon will not be as bright, LaCoursiere said. Viewing of the Perseids lasts until August 23. What is a meteor shower? As the Earth orbits the sun, several times a year it passes through debris left by passing comets and sometimes asteroids. The source of the Perseids is debris from comet 109P/Swift-Tuttle. When these fast-moving space rocks enter Earth's atmosphere, the debris encounters new resistance from the air and becomes very hot, eventually burning up. Sometimes the surrounding air glows briefly, leaving behind a fiery tail — the end of a 'shooting star.' You don't need special equipment to see the various meteor showers that flash across annually, just a spot away from city lights. How to view a meteor shower The best time to watch a meteor shower is in the early predawn hours when the moon is low in the sky. Competing sources of light — such as a bright moon or artificial glow — are the main obstacles to a clear view of meteors. Cloudless nights when the moon wanes smallest are optimal viewing opportunities. And keep looking up, not down. Your eyes will be better adapted to spot shooting stars if you aren't checking your phone. When is the next meteor shower? The next major meteor shower, the Orionids, peaks in late October. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content. Christina Larson, The Associated Press
Globe and Mail
6 hours ago
- Globe and Mail
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency. In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership. With the successful launch of our proprietary AI-driven PredicTcell™ platform, we've significantly enhanced target discovery efficiency. Strategic partnerships with global technology leaders, such as Microsoft and Databricks, have accelerated our progress. Recent patent filings further secure our intellectual property in AI-driven predictive modeling, positioning us at the forefront of innovation. Importantly, Tevogen Bio is well capitalized, having access to necessary funding we may require to fully execute our current growth strategy, including the accelerated development of While the sector faces significant challenges, our company continues to grow, underscoring the foundational strength of our company. We deeply appreciate your continued support as we work toward our vision of transforming healthcare through democratizing access. It feels good to be part of this growth story and am grateful to my colleagues at Tevogen for their exceptional expertise, dedication, and, above all, their compassion for others. Sincerely, Ryan Saadi, MD, MPH Founder and CEO, Tevogen Bio Recent Announcements Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts T: 1 877 TEVOGEN, Ext 701
National Post
a day ago
- National Post
Colby Cosh: The atomic bomb through Oppenheimer's eyes
Can it really be two years since Christopher Nolan's film 'Oppenheimer' became the old-school box-office sensation of summer 2023? Well, there you go, it must have been two years: even a journalist can do that much math. 'Oppenheimer,' which is reasonably scrupulous in its accuracy by cinema standards, continues to be fertile ground for discussion and memes. People will go on talking about the war and the command decision to bomb, but the drama of Los Alamos, N.M., is a distinctive, important historical phenomenon, a little nugget of uncanny magic rearranging human history at the outset of the Jet Age. Article content Article content A cult of wizards was assembled (on a mountaintop, loosely speaking) by a great empire: it was told to come up with a method to drop a sun on its enemies, and they succeeded. As Nolan's movie implies, almost every other thing that happened in the 20th century, including the actual use of the weapon, might be a footnote. Article content Article content Article content If you are suitably mesmerized by these events, one thing to remember is that the record of them is still incomplete. 'Oppenheimer' was made even though documentary material about, and by, J. Robert Oppenheimer is still becoming available to the public, as a new National Security Archive (NSA) release reminded us on Tuesday. The NSA maintains a 'briefing book' of primary sources on the bombings of Hiroshima and Nagasaki, and it makes periodic updates with newly declassified or rediscovered materials. The briefing book itself, built up over 20 years, is extensive enough to fertilize graduate-level papers on the decisions surrounding construction and use of the bomb. Article content Article content There are some fascinating new declassified documents in the 2025 update. One is a letter written in September 1944 by William S. Parsons, the navy officer who headed the ordnance group at Los Alamos. Parsons led the creation of the 'gun' design used for Little Boy, the bomb dropped on Hiroshima, and he would fly on the mission that delivered it. But he also had an administrative role as a voice of, and pair of eyes for, the professional military among the civilian boffins at Los Alamos. Article content Article content Parsons' letter is addressed to Maj.-Gen. Leslie Groves, overall boss of the Manhattan Project, and was delivered by Oppenheimer, which is why it sits in a file folder among the Oppenheimer Papers at the Library of Congress. Article content The letter is Parsons' rambling argument, extraordinary in historical retrospect, against any mere testing of a nuclear weapon. Plans for what became the Trinity test in the New Mexico desert were already coming into view, and the American high command was then still wondering whether to invite representatives of the Axis governments. Parsons points out morbidly that the most impressive test, the most convincing demonstration, would be to detonate the bomb 'one thousand feet over Times Square.' Short of that, he did not see the point of setting one off in the desert amid a few unoccupied temporary structures when it could just be dropped on an enemy. 'Even the crater would be disappointing.'
